Cargando…
Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
Autores principales: | Fu, Wenyu, Chen, Yujianan, Wang, Kaidi, Hettinghouse, Aubryanna, Hu, Wenhuo, Wang, Jing-Quan, Lei, Zi-Ning, Chen, Zhe-Sheng, Stapleford, Kenneth A., Liu, Chuan-ju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673315/ https://www.ncbi.nlm.nih.gov/pubmed/33210243 http://dx.doi.org/10.1007/s13238-020-00803-w |
Ejemplares similares
-
Atsttrin Promotes Cartilage Repair Primarily Through TNFR2-Akt Pathway
por: Wei, Jianlu, et al.
Publicado: (2020) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016) -
Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016) -
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022) -
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)